CN107058357A - A kind of TA cloning vectors and its construction method and application based on digestion - Google Patents
A kind of TA cloning vectors and its construction method and application based on digestion Download PDFInfo
- Publication number
- CN107058357A CN107058357A CN201710147060.XA CN201710147060A CN107058357A CN 107058357 A CN107058357 A CN 107058357A CN 201710147060 A CN201710147060 A CN 201710147060A CN 107058357 A CN107058357 A CN 107058357A
- Authority
- CN
- China
- Prior art keywords
- digestion
- cloning vectors
- pcr fragment
- minutes
- cloning
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明属于分子生物学领域,具体地说,涉及一种基于酶切的TA克隆载体及其构建方法和应用。The invention belongs to the field of molecular biology, and in particular relates to a TA cloning vector based on enzyme cutting and its construction method and application.
背景技术Background technique
TA克隆是目前克隆PCR产物最简便、快捷、经济的方法,在分子生物学领域应用极其广泛。根据反应过程中使用的酶的种类,TA克隆可主要分为两类,一类是基于T4DNA连接酶,一类是基于DNA拓扑异构酶I(TOPO),其中前者载体制备容易,成本低,高效连接耗时长,后者载体制备繁琐,成本高,高效连接耗时极短。根据载体产生T末端的方式,有利用转移酶在PCR产物末端加T和酶切产生T末端两种,前者通量高,一致性差,后者通量略低,一致性好。TA cloning is currently the most convenient, fast and economical method for cloning PCR products, and it is widely used in the field of molecular biology. According to the types of enzymes used in the reaction process, TA cloning can be mainly divided into two categories, one is based on T4 DNA ligase, and the other is based on DNA topoisomerase I (TOPO). The former vector is easy to prepare and low in cost. High-efficiency connection takes a long time, the preparation of the latter carrier is cumbersome and costly, and high-efficiency connection takes a very short time. According to the method of generating T-terminus of the vector, there are two ways to use transferase to add T to the end of the PCR product and to generate T-terminus by enzymatic digestion. The former has high throughput and poor consistency, while the latter has slightly lower flux and good consistency.
发明内容Contents of the invention
有鉴于此,本发明针对上述的问题,提供了一种基于酶切的TA克隆载体及其构建方法和应用,该TA克隆载体可靠性高,一致性好,成本低廉,中小型实验室即可使用。In view of this, the present invention aims at the above problems, and provides a TA cloning vector based on enzyme cutting and its construction method and application. The TA cloning vector has high reliability, good consistency, and low cost, and can be used in small and medium-sized laboratories. use.
为了解决上述技术问题,本发明公开了一种基于酶切的TA克隆载体,所述基于酶切的TA克隆载体的核苷酸序列如SEQ ID NO.1所示,命名为pTA03载体。In order to solve the above technical problems, the present invention discloses a TA cloning vector based on enzyme cutting, the nucleotide sequence of the TA cloning vector based on enzyme cutting is shown in SEQ ID NO.1, named as pTA03 vector.
本发明还提供一种基于酶切的TA克隆载体的构建方法,包括以下步骤:取3-5μgpTA03载体,37℃条件下用限制性内切酶AhdI酶切消化3-18小时,酶切结束后补加少量EcoRV-HF内切酶消化30分钟,65℃保持20分钟,酶切产物采用酶切试剂盒直接过柱回收,或者用DNA凝胶回收试剂盒回收;回收产物-20℃保存,该产物即为制备好的TA克隆载体。The present invention also provides a method for constructing a TA cloning vector based on enzyme digestion, comprising the following steps: take 3-5 μg of the pTA03 vector, digest it with the restriction endonuclease AhdI for 3-18 hours at 37°C, and Add a small amount of EcoRV-HF endonuclease to digest for 30 minutes, keep at 65°C for 20 minutes, and use the enzyme digestion kit to directly pass through the column to recover the digested product, or use the DNA gel recovery kit to recover; the recovered product should be stored at -20°C. The product is the prepared TA cloning vector.
本发明还提供一种上述的基于酶切的TA克隆载体的使用方法,包括以下步骤:The present invention also provides a method for using the above enzyme-based TA cloning vector, comprising the following steps:
步骤1、制备基于酶切的TA克隆载体:取3-5μg pTA03载体,37℃条件下用限制性内切酶AhdI酶切消化3-18小时,酶切结束后补加少量EcoRV-HF内切酶消化30分钟,65℃保持20分钟,酶切产物采用酶切试剂盒直接过柱回收,或者用DNA凝胶回收试剂盒回收;回收产物-20℃保存,该产物即为制备好的TA克隆载体;Step 1. Preparation of TA cloning vector based on enzyme digestion: take 3-5 μg of pTA03 vector, digest it with restriction endonuclease AhdI for 3-18 hours at 37°C, and add a small amount of EcoRV-HF endogenous digestion after enzyme digestion Enzyme digested for 30 minutes, kept at 65°C for 20 minutes, and the digested product was recovered directly through the column with an enzyme digestion kit, or recovered with a DNA gel recovery kit; the recovered product was stored at -20°C, and the product was the prepared TA clone carrier;
步骤2、将步骤1制备好的基于酶切的TA克隆载体与目的PCR片段混合配制连接反应体系,混匀后短暂离心3-5秒,将混合液于22度反应5分钟,反应结束后置冰上,进行后续的转化反应。Step 2. Mix the TA cloning vector based on enzyme digestion prepared in step 1 and the target PCR fragment to prepare a ligation reaction system. After mixing, centrifuge briefly for 3-5 seconds, and react the mixture at 22 degrees for 5 minutes. On ice, carry out subsequent transformation reactions.
进一步地,步骤1中的酶切反应体系具体为:10xCutSmart Buffer(NEB)10μL,10U/μL的限制性内切酶AhdI 2μL,1μg/μl的基于酶切的TA克隆载体5μL,余量为H2O,以上体积总量为100μL。Further, the enzyme digestion reaction system in step 1 is specifically: 10 μL of 10xCutSmart Buffer (NEB), 2 μL of restriction endonuclease AhdI of 10 U/μL, 5 μL of TA cloning vector based on enzyme digestion of 1 μg/μl, and the balance is H 2 O, the total volume of the above is 100 μL.
进一步地,步骤2中的连接反应体系具体为:10xT4DNA ligase Buffer(NEB)1μL,400U/μL的T4DNA ligase 0.5μL,50ng/μL的基于酶切的TA克隆载体1μL,目的PCR片段与基于酶切的TA克隆载体的摩尔比为3~7∶1,余量为ddH2O,以上体积总量为100μL。Further, the ligation reaction system in step 2 is specifically: 1 μL of 10xT4DNA ligase Buffer (NEB), 0.5 μL of 400 U/μL T4DNA ligase, 1 μL of TA cloning vector based on enzyme digestion at 50 ng/μL, and the target PCR fragment and enzyme-based digestion The molar ratio of the TA cloning vector is 3-7:1, the balance is ddH 2 O, and the total volume of the above is 100 μL.
进一步地,连接体系中的基于酶切的TA克隆载体的添加量为0.03pmol,当目的PCR片段的长度在2000bp以下时,目的PCR片段:基于酶切的TA克隆载体的摩尔比为7∶1,22℃连接5分钟;当目的PCR片段的长度在2000bp以上时,目的PCR片段:TA克隆载体的摩尔比为3∶1,22℃连接30分钟。Further, the addition amount of the TA cloning vector based on enzyme cutting in the ligation system is 0.03pmol, and when the length of the target PCR fragment is below 2000bp, the molar ratio of the target PCR fragment: the TA cloning vector based on enzyme cutting is 7:1 , ligated for 5 minutes at 22°C; when the length of the target PCR fragment was more than 2000bp, the molar ratio of the target PCR fragment: TA cloning vector was 3:1, ligated for 30 minutes at 22°C.
进一步地,目的PCR片段的用量(μl)=[660×A×0.03×B(ng)]÷[1000×目的PCR片段浓度(ng/μl)],其中A是目的PCR片段的碱基对数(bp),B是PCR片段:TA克隆载体的摩尔比。Further, the amount of the target PCR fragment (μl)=[660×A×0.03×B(ng)]÷[1000×the concentration of the target PCR fragment (ng/μl)], where A is the number of base pairs of the target PCR fragment (bp), B is the molar ratio of PCR fragment: TA cloning vector.
与现有技术相比,本发明可以获得包括以下技术效果:Compared with prior art, the present invention can obtain and comprise following technical effect:
1)本发明TA克隆载体制备简单,成本低,酶切一次可制备大量载体;1) The TA cloning vector of the present invention is simple to prepare and low in cost, and a large number of vectors can be prepared by one enzyme digestion;
2)本发明TA克隆载体可靠性高,一致性好,末端基本全部带T;2) The TA cloning vector of the present invention has high reliability and good consistency, and basically all ends have T;
3)本发明TA克隆载体携带致死基因,无需蓝白斑筛选,阳性率接近100%。3) The TA cloning vector of the present invention carries a lethal gene, which does not require blue-white screening, and the positive rate is close to 100%.
当然,实施本发明的任一产品并不一定需要同时达到以上所述的所有技术效果。Of course, implementing any product of the present invention does not necessarily need to achieve all the technical effects described above at the same time.
附图说明Description of drawings
此处所说明的附图用来提供对本发明的进一步理解,构成本发明的一部分,本发明的示意性实施例及其说明用于解释本发明,并不构成对本发明的不当限定。在附图中:The accompanying drawings described here are used to provide a further understanding of the present invention, and constitute a part of the present invention. The schematic embodiments of the present invention and their descriptions are used to explain the present invention, and do not constitute improper limitations to the present invention. In the attached picture:
图1是本发明基于酶切的TA克隆载体的图谱;Fig. 1 is the schematic diagram of the TA cloning vector based on enzyme cutting of the present invention;
图2是本发明阳性菌在LB/Amp平板培养基上的生长情况;Fig. 2 is the growth situation of positive bacteria of the present invention on LB/Amp plate culture medium;
图3是本发明不同菌落PCR鉴定结果,其中,M为D2000DNA Marker,1-6为随机的PCR鉴定。Fig. 3 is the result of PCR identification of different colonies of the present invention, wherein, M is D2000 DNA Marker, and 1-6 are random PCR identifications.
具体实施方式detailed description
以下将配合实施例来详细说明本发明的实施方式,藉此对本发明如何应用技术手段来解决技术问题并达成技术功效的实现过程能充分理解并据以实施。The implementation of the present invention will be described in detail below with examples, so as to fully understand and implement the implementation process of how the present invention uses technical means to solve technical problems and achieve technical effects.
实施例1基于酶切的TA克隆载体及其构建方法Embodiment 1 Restriction-based TA cloning vector and construction method thereof
本发明提供一种基于酶切的TA克隆载体,本载体由pUC19载体为骨架构建而成,不含多克隆位点,携带ccdB致死基因,阳性率接近100%,适用于DNA测序。采用限制性内切酶AhdI酶切该载体后,纯化回收即得到线性化的TA克隆载体,命名为pTA03载体。该载体图谱如图1所示,TA克隆载体的核苷酸序列如SEQ ID NO.1所示,其目标片段序列如下:其中分别是M13fwd和M13rev引物序列,是AmpR序列,是限制性内切酶AhdI序列,加粗部分为ccdB致死基因片段。The present invention provides a TA cloning vector based on enzyme cutting, which is constructed from pUC19 vector as the backbone, does not contain multiple cloning sites, carries ccdB lethal gene, has a positive rate close to 100%, and is suitable for DNA sequencing. After the vector was digested with the restriction endonuclease AhdI, the linearized TA cloning vector was obtained after purification and recovery, which was named pTA03 vector. The vector map is shown in Figure 1, the nucleotide sequence of the TA cloning vector is shown in SEQ ID NO.1, and its target fragment sequence is as follows: wherein are the M13fwd and M13rev primer sequences, respectively, is the AmpR sequence, It is the restriction endonuclease AhdI sequence, and the bold part is the ccdB lethal gene fragment.
TA克隆载体的核苷酸序列如下:The nucleotide sequence of the TA cloning vector is as follows:
实施例2基于酶切的TA克隆载体的构建及使用方法Embodiment 2 The construction and use method of the TA cloning vector based on enzyme cutting
取3-5μg pTA03质粒,用限制性内切酶AhdI酶切消化3-18小时,酶切结束后补加少量EcoRV-HF内切酶消化30分钟,65℃保持20分钟,酶切产物采用酶切试剂盒直接过柱回收,也可用DNA凝胶回收试剂盒回收。回收产物-20℃保存,该产物即为制备好的TA克隆载体,可以用T4DNA连接酶与PCR产物进行TA连接,连接产物无需蓝白斑筛选。Take 3-5μg pTA03 plasmid, digest with restriction endonuclease AhdI for 3-18 hours, add a small amount of EcoRV-HF endonuclease to digest for 30 minutes, keep at 65°C for 20 minutes, and digest the product with enzyme The cutting kit can be directly recovered through the column, and the DNA gel recovery kit can also be used for recovery. The recovered product is stored at -20°C. This product is the prepared TA cloning vector. T4 DNA ligase can be used to perform TA ligation with the PCR product, and the ligated product does not need to be screened by blue and white spots.
实施例3Example 3
1.载体线性化:如表1所示,配制酶切体系,37℃反应3-18小时,酶切结束后补加1μl EcoRV-HF内切酶(NEB)消化30分钟,65℃保持20分钟,酶切产物采用酶切试剂盒直接过柱回收,也可用DNA凝胶回收试剂盒回收,回收产物-20℃保存,该产物即为制备好的TA克隆载体,可以用T4DNA连接酶与PCR产物进行TA连接。1. Vector linearization: As shown in Table 1, prepare enzyme digestion system, react at 37°C for 3-18 hours, add 1 μl EcoRV-HF endonuclease (NEB) to digest for 30 minutes after enzyme digestion, and keep at 65°C for 20 minutes , the digested product can be recovered directly through the column with the enzyme digestion kit, or can be recovered with the DNA gel recovery kit, and the recovered product can be stored at -20°C. Make a TA connection.
表1酶切反应体系Table 1 enzyme digestion reaction system
2.TA连接:如表2所示,按照目的PCR片段:TA克隆载体的摩尔比为3~7∶1配制连接反应体系,混匀后短暂离心3-5秒,将混合液于22℃反应5分钟,反应结束后置冰上,进行后续的转化反应。2. TA connection: As shown in Table 2, prepare the connection reaction system according to the molar ratio of the target PCR fragment: TA cloning carrier at 3-7:1, mix well and centrifuge briefly for 3-5 seconds, and react the mixture at 22°C After 5 minutes, put it on ice after the reaction, and carry out the subsequent transformation reaction.
表2连接反应体系Table 2 Connection reaction system
注:(1)连接体系中加入的基于酶切的TA克隆载体为0.03pmol,当目的PCR片段的长度在2000bp以下时建议目的PCR片段:TA克隆载体的摩尔比为7∶1,22℃连接5分钟;当目的PCR片段的长度在2000bp以上时建议目的PCR片段:TA克隆载体的摩尔比为3∶1,22℃连接30分钟;Note: (1) The TA cloning carrier based on enzyme digestion added in the ligation system is 0.03pmol. When the length of the target PCR fragment is less than 2000bp, it is recommended that the molar ratio of the target PCR fragment: TA cloning carrier be 7:1, and ligate at 22°C 5 minutes; when the length of the target PCR fragment is more than 2000bp, it is recommended that the molar ratio of the target PCR fragment:TA cloning vector is 3:1, and ligate at 22°C for 30 minutes;
(2)目的PCR片段的用量(μl)=[660×A×0.03×B(ng)]÷[1000×目的PCR片段浓度(ng/μl)],其中A是目的PCR片段的碱基对数(bp),B是PCR片段:TA克隆载体的摩尔比。(2) The amount of the target PCR fragment (μl)=[660×A×0.03×B(ng)]÷[1000×the concentration of the target PCR fragment (ng/μl)], where A is the number of base pairs of the target PCR fragment (bp), B is the molar ratio of PCR fragment: TA cloning vector.
(3)转化的菌株应尽量选择不含laqI基因的,如DH5a,TOP10,T1等,如需使用JM109菌株,应在平板培养基上添加少量IPTG。(3) The transformed bacterial strain should try to choose one that does not contain the laqI gene, such as DH5a, TOP10, T1, etc. If you need to use the JM109 strain, you should add a small amount of IPTG to the plate medium.
实施例4Example 4
如表3所示,按照目的PCR片段(约150bp):TA克隆载体的摩尔比为7∶1配制连接反应体系,该目的PCR片段为FaMYB5基因,其序列如SEQ ID NO.2所示,混匀后短暂离心3-5秒,将混合液于22℃反应5分钟,反应结束后置冰上,取全部产物转化DH5a。图2为阳性菌在LB/Amp平板培养基上的生长情况,随机挑取6个菌落,使用M13fwd和M13rev引物进行菌落PCR鉴定,如图3所示,结果显示扩增的条带均与预期大小(约500bp)完全相同,进一步的测序显示目标片段接入均完全正确,这也证实了用本发明得到的TA重组载体阳性率接近100%。As shown in Table 3, the ligation reaction system was prepared according to the target PCR fragment (about 150bp): TA cloning vector molar ratio of 7:1, the target PCR fragment is the FaMYB5 gene, its sequence is shown in SEQ ID NO.2, mixed After homogenization, briefly centrifuge for 3-5 seconds, react the mixture at 22°C for 5 minutes, put it on ice after the reaction, and take all the products to transform into DH5a. Figure 2 shows the growth of positive bacteria on the LB/Amp plate medium, randomly picked 6 colonies, and used M13fwd and M13rev primers to carry out colony PCR identification, as shown in Figure 3, the results showed that the amplified bands were all in line with expectations The sizes (about 500bp) are exactly the same, and further sequencing shows that the insertion of the target fragments is completely correct, which also confirms that the positive rate of the TA recombinant vector obtained by the present invention is close to 100%.
表3连接反应体系Table 3 Connection reaction system
上述说明示出并描述了发明的若干优选实施例,但如前所述,应当理解发明并非局限于本文所披露的形式,不应看作是对其他实施例的排除,而可用于各种其他组合、修改和环境,并能够在本文所述发明构想范围内,通过上述教导或相关领域的技术或知识进行改动。而本领域人员所进行的改动和变化不脱离发明的精神和范围,则都应在发明所附权利要求的保护范围内。The above description shows and describes several preferred embodiments of the invention, but as previously stated, it should be understood that the invention is not limited to the form disclosed herein, and should not be regarded as excluding other embodiments, but can be used in various other embodiments. Combinations, modifications and circumstances, and can be modified within the scope of the inventive concept described herein, by the above teachings or by skill or knowledge in the relevant field. However, changes and changes made by those skilled in the art do not depart from the spirit and scope of the invention, and should be within the protection scope of the appended claims of the invention.
SEQUENCE LISTINGSEQUENCE LISTING
<110> 四川农业大学<110> Sichuan Agricultural University
<120> 一种基于酶切的TA克隆载体及其构建方法和应用<120> A TA Cloning Vector Based on Enzyme Cutting and Its Construction Method and Application
<130> 2017<130> 2017
<160> 2<160> 2
<170> PatentIn version 3.3<170> PatentIn version 3.3
<210> 1<210> 1
<211> 2721<211> 2721
<212> DNA<212>DNA
<213> 人工合成<213> Synthetic
<400> 1<400> 1
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 60tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 120cagcttgtct gtaagcggat gccggggagca gacaagcccg tcagggcgcg tcagcgggtg 120
ttggcgggtg tcggggctgg cttaagtaaa acgacggcca gtttatattc cccagaacat 180ttggcgggtg tcggggctgg cttaagtaaa acgacggcca gtttatattc cccagaacat 180
caggttaatg gcgtttttga tgtcattttc gcggtggctg agatcagcca cttcttcccc 240caggttaatg gcgtttttga tgtcattttc gcggtggctg agatcagcca cttcttcccc 240
gataacggag accggcacac tggccatatc ggtggtcatc atgcgccagc tttcatcccc 300gataacggag accggcacac tggccatatc ggtggtcatc atgcgccagc tttcatcccc 300
gatatgcacc accgggtaaa gttcacggga gactttatct gacagtcagt cgatatcgat 360gatatgcacc accgggtaaa gttcacggga gactttatct gacagtcagt cgatatcgat 360
atcgatatcg atatcgacag acagtcgtgc actggccagg gggatcacca tccgtcgccc 420atcgatatcg atatcgacag acagtcgtgc actggccagg gggatcacca tccgtcgccc 420
cggcgtgtca ataatatcac tctgtacatc cacaaacaga cgataacggc tctctctttt 480cggcgtgtca ataatatcac tctgtacatc cacaaacaga cgataacggc tctctctttt 480
ataggtgtaa accttaaact gcatagctgt ttcctgtgtg aaattgttat ccgctcacaa 540ataggtgtaa accttaaact gcatagctgt ttcctgtgtg aaattgttat ccgctcacaa 540
ttccacacat tatacgagcc ggaagcataa agtgtaaagc ctggggtgcc taatgagtga 600ttccacacat tatacgagcc ggaagcataa agtgtaaagc ctggggtgcc taatgagtga 600
gctaactcac attaattgcg ttgcgctcac tgcccgcttt ccagtcggga aacctgtcgt 660gctaactcac attaattgcg ttgcgctcac tgcccgcttt ccagtcggga aacctgtcgt 660
gccagctgca ttaatgaatc ggccaacgcg cggggagagg cggtttgcgt attgggcgct 720gccagctgca ttaatgaatc ggccaacgcg cggggagagg cggtttgcgt attgggcgct 720
cttccgcttc ctcgctcact gactcgctgc gctcggtcgt tcggctgcgg cgagcggtat 780cttccgcttc ctcgctcact gactcgctgc gctcggtcgt tcggctgcgg cgagcggtat 780
cagctcactc aaaggcggta atacggttat ccacagaatc aggggataac gcaggaaaga 840cagctcactc aaaggcggta atacggttat ccacagaatc aggggataac gcaggaaaga 840
acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt 900acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt 900
ttttccatag gctccgcccc cctgacgagc atcacaaaaa tcgacgctca agtcagaggt 960ttttccatag gctccgcccc cctgacgagc atcacaaaaa tcgacgctca agtcagaggt 960
ggcgaaaccc gacaggacta taaagatacc aggcgtttcc ccctggaagc tccctcgtgc 1020ggcgaaaccc gacaggacta taaagatacc aggcgtttcc ccctggaagc tccctcgtgc 1020
gctctcctgt tccgaccctg ccgcttaccg gatacctgtc cgcctttctc ccttcgggaa 1080gctctcctgt tccgaccctg ccgcttaccg gatacctgtc cgcctttctc ccttcgggaa 1080
gcgtggcgct ttctcatagc tcacgctgta ggtatctcag ttcggtgtag gtcgttcgct 1140gcgtggcgct ttctcatagc tcacgctgta ggtatctcag ttcggtgtag gtcgttcgct 1140
ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga ccgctgcgcc ttatccggta 1200ccaagctggg ctgtgtgcac gaacccccccg ttcagcccga ccgctgcgcc ttatccggta 1200
actatcgtct tgagtccaac ccggtaagac acgacttatc gccactggca gcagccactg 1260actatcgtct tgagtccaac ccggtaagac acgacttatc gccactggca gcagccactg 1260
gtaacaggat tagcagagcg aggtatgtag gcggtgctac agagttcttg aagtggtggc 1320gtaacaggat tagcagagcg aggtatgtag gcggtgctac agagttcttg aagtggtggc 1320
ctaactacgg ctacactaga agaacagtat ttggtatctg cgctctgctg aagccagtta 1380ctaactacgg ctacactaga agaacagtat ttggtatctg cgctctgctg aagccagtta 1380
ccttcggaaa aagagttggt agctcttgat ccggcaaaca aaccaccgct ggtagcggtg 1440ccttcggaaa aagagttggt agctcttgat ccggcaaaca aaccaccgct ggtagcggtg 1440
gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt 1500gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt 1500
tgatcttttc tacggggtct gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg 1560tgatcttttc tacggggtct gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg 1560
tcatgagatt atcaaaaagg atcttcacct agatcctttt aaattaaaaa tgaagtttta 1620tcatgagatt atcaaaaagg atcttcacct agatcctttt aaattaaaaa tgaagtttta 1620
aatcaatcta aagtatatat gagtaaactt ggtctgacag ttaccaatgc ttaatcagtg 1680aatcaatcta aagtatatat gagtaaactt ggtctgacag ttaccaatgc ttaatcagtg 1680
aggcacctat ctcagcgatc tgtctatttc gttcatccat agttgcctgg ctccccgtcg 1740aggcacctat ctcagcgatc tgtctatttc gttcatccat agttgcctgg ctccccgtcg 1740
tgtagataac tacgatacgg gagggcttac catctggccc cagtgctgca atgataccgc 1800tgtagataac tacgatacgg gagggcttac catctggccc cagtgctgca atgataccgc 1800
gagacccacg ctcaccggct ccagatttat cagcaataaa ccagccagcc ggaagggccg 1860gagaccacg ctcaccggct ccagatttat cagcaataaa ccagccagcc ggaagggccg 1860
agcgcagaag tggtcctgca actttatccg cctccatcca gtctattaat tgttgccggg 1920agcgcagaag tggtcctgca actttatccg cctccatcca gtctattaat tgttgccggg 1920
aagctagagt aagtagttcg ccagttaata gtttgcgcaa cgttgttgcc attgctacag 1980aagctagagt aagtagttcg ccagttaata gtttgcgcaa cgttgttgcc attgctacag 1980
gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt cagctccggt tcccaacgat 2040gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt cagctccggt tcccaacgat 2040
caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc ggttagctcc ttcggtcctc 2100caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc ggttagctcc ttcggtcctc 2100
cgatcgttgt cagaagtaag ttggccgcag tgttatcact catggttatg gcagcactgc 2160cgatcgttgt cagaagtaag ttggccgcag tgttatcact catggttatg gcagcactgc 2160
ataattctct tactgtcatg ccatccgtaa gatgcttttc tgtgactggt gagtactcaa 2220ataattctct tactgtcatg ccatccgtaa gatgcttttc tgtgactggt gagtactcaa 2220
ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg ctcttgcccg gcgtcaatac 2280ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg ctcttgcccg gcgtcaatac 2280
gggataatac cgcgccacat agcagaactt taaaagtgct catcattgga aaacgttctt 2340gggataatac cgcgccacat agcagaactt taaaagtgct catcattgga aaacgttctt 2340
cggggcgaaa actctcaagg atcttaccgc tgttgagatc cagttcgatg taacccactc 2400cggggcgaaa actctcaagg atcttaccgc tgttgagatc cagttcgatg taacccactc 2400
gtgcacccaa ctgatcttca gcatctttta ctttcaccag cgtttctggg tgagcaaaaa 2460gtgcacccaa ctgatcttca gcatctttta ctttcaccag cgtttctggg tgagcaaaaa 2460
caggaaggca aaatgccgca aaaaagggaa taagggcgac acggaaatgt tgaatactca 2520caggaaggca aaatgccgca aaaaagggaa taagggcgac acggaaatgt tgaatactca 2520
tactcttcct ttttcaatat tattgaagca tttatcaggg ttattgtctc atgagcggat 2580tactcttcct ttttcaatat tattgaagca tttatcaggg ttaattgtctc atgagcggat 2580
acatatttga atgtatttag aaaaataaac aaataggggt tccgcgcaca tttccccgaa 2640acatatttga atgtatttag aaaaataaac aaataggggt tccgcgcaca tttccccgaa 2640
aagtgccacc tgacgtctaa gaaaccatta ttatcatgac attaacctat aaaaataggc 2700aagtgccacc tgacgtctaa gaaaccatta ttatcatgac attaacctat aaaaataggc 2700
gtatcacgag gccctttcgt c 2721gtatcacgag gccctttcgt c 2721
<210> 2<210> 2
<211> 139<211> 139
<212> DNA<212>DNA
<213> FaMYB5基因<213> FaMYB5 gene
<400> 2<400> 2
tcctcggcaa tagatggtcc ctgattgctg ggaggattcc ggggcgaacg gacaatgaga 60tcctcggcaa tagatggtcc ctgattgctg ggaggattcc ggggcgaacg gacaatgaga 60
taaagaacta ctggaacact cacctcagta agaagctgat tagtcagggc atagatccca 120taaagaacta ctggaacact cacctcagta agaagctgat tagtcagggc atagatccca 120
gaacccacaa gccactcaa 139gaacccacaa gccactcaa 139
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710147060.XA CN107058357A (en) | 2017-03-13 | 2017-03-13 | A kind of TA cloning vectors and its construction method and application based on digestion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710147060.XA CN107058357A (en) | 2017-03-13 | 2017-03-13 | A kind of TA cloning vectors and its construction method and application based on digestion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107058357A true CN107058357A (en) | 2017-08-18 |
Family
ID=59623078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710147060.XA Pending CN107058357A (en) | 2017-03-13 | 2017-03-13 | A kind of TA cloning vectors and its construction method and application based on digestion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107058357A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5487993A (en) * | 1990-09-27 | 1996-01-30 | Invitrogen Corporation | Direct cloning of PCR amplified nucleic acids |
| KR20010104589A (en) * | 2000-05-15 | 2001-11-26 | 윤경홍 | PCR T/A cloning vector for cloning PCR product by single enzyme digestion and process for preparing thereof |
| CN1590549A (en) * | 2004-06-10 | 2005-03-09 | 清华大学 | Method of constructing T carrier |
| WO2005021747A1 (en) * | 2003-09-01 | 2005-03-10 | Yokohama City University | Novel vector and utilization of the same |
| CN101503698A (en) * | 2009-03-06 | 2009-08-12 | 西南大学 | Non-false positive T vector and preparation |
| CN101948862A (en) * | 2010-09-13 | 2011-01-19 | 原平皓(天津)生物技术有限公司 | T vector construction method |
-
2017
- 2017-03-13 CN CN201710147060.XA patent/CN107058357A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5487993A (en) * | 1990-09-27 | 1996-01-30 | Invitrogen Corporation | Direct cloning of PCR amplified nucleic acids |
| KR20010104589A (en) * | 2000-05-15 | 2001-11-26 | 윤경홍 | PCR T/A cloning vector for cloning PCR product by single enzyme digestion and process for preparing thereof |
| WO2005021747A1 (en) * | 2003-09-01 | 2005-03-10 | Yokohama City University | Novel vector and utilization of the same |
| CN1590549A (en) * | 2004-06-10 | 2005-03-09 | 清华大学 | Method of constructing T carrier |
| CN101503698A (en) * | 2009-03-06 | 2009-08-12 | 西南大学 | Non-false positive T vector and preparation |
| CN101948862A (en) * | 2010-09-13 | 2011-01-19 | 原平皓(天津)生物技术有限公司 | T vector construction method |
Non-Patent Citations (2)
| Title |
|---|
| MESSING,J: "Cloning vector pUC19,complete sequence", 《GENBANK:M77789.2》 * |
| PHILIPPE BERNARD等: "Positive-selection vectors using the F plasmid ccdB killer gene", 《GENE》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108753813B (en) | Methods of obtaining marker-free transgenic plants | |
| CN107916275B (en) | Method for aerobic synthesis of succinic acid by yarrowia lipolytica strain with TCA reduction pathway | |
| CN108486105B (en) | Kluyveromyces marxianus promoter as well as preparation method and application thereof | |
| CN107475267B (en) | 4-hydroxyisoleucine production plasmid and strain and synthesis method of 4-hydroxyisoleucine | |
| CN110540989A (en) | Primer and method for cloning unknown DNA sequence adjacent to known region based on PCR technology | |
| CN101775410B (en) | Fowlpox virus vector shuttle plasmid and application thereof | |
| CN101693901B (en) | An Escherichia coli-coryneform bacteria shuttle inducible expression vector pDXW-8 and its construction method | |
| CN111171132A (en) | snakehead antibacterial peptide | |
| CN101302531A (en) | A kind of BAC vector and its construction method for shuttle expression between Escherichia coli-Streptomyces-Pseudomonas | |
| WO1994026913A9 (en) | Marker gene | |
| KR101578444B1 (en) | Recombinant foot-and-mouth disease virus using Korean isolated strain of FMDV A serotype and the manufacturing method | |
| CN108410870B (en) | Kluyveromyces marxianus promoter, secretion signal peptide, preparation and application thereof | |
| AU2020103156A4 (en) | A TA Cloning Vector Based on Enzyme Digestion and Its Construction Method | |
| CN108728484B (en) | Vector for obtaining marker-free transgenic plants and its application | |
| CN110004131A (en) | A kind of molecular modification method improving lysine decarboxylase activity and stability | |
| CN104450768B (en) | A kind of shuttle vector for targeting yeast mitochondrial and its application | |
| CN110157721A (en) | A tracer targeting plasmid of vaccinia virus Tiantan strain and preparation method thereof | |
| CN107058357A (en) | A kind of TA cloning vectors and its construction method and application based on digestion | |
| CN110305873A (en) | Co-editing marker ben-1 sgRNA target site and its CRISPR/Cas9 co-editing system and application | |
| CN115369099B (en) | Rhizomucor miehei lipase mutant and method for improving activity and/or methanol tolerance of Rhizomucor miehei lipase | |
| CN115109791B (en) | Functional gene delivery vector based on IncQ plasmid flood host, construction method and application | |
| CN113373163B (en) | Codon-optimized Chlamydia trachomatis ctl0286 gene and application thereof | |
| US20100304461A1 (en) | Portable, Temperature and Chemically Inducible Expression Vector for High Cell Density Expression of Heterologous Genes in Escherichia Coli | |
| CN104673832B (en) | A method of assembling TALE/TALEN modules | |
| KR101629345B1 (en) | Foot and mouth disease virus expressing P1-protective antigen of Asia1 type, IV genotype and the manufacturing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170818 |